IngredientsCrocin is formally named all-trans crocetin di-β-D-gentiobiosyl ester and carries the molecular formula C44H64O24. Crocin (all-trans crocetin di-β-D-gentiobiosyl ester) is a glycoside carotenoid endowed with several health benefits, including antioxidant, anticancer, antidepressant, anxiolytic, cardioprotective, and neuroprotective activity. From a chemical point of view, crocin is a diester consisting of the disaccharide gentiobiose and the dicarboxylic acid crocetin. Crocin belongs to the broader apocarotenoid class; crocin belongs to the "crocin" family, consisting of hydrophilic carotenoids in which D-glucose and/or D-gentiobiose residues form either mono- or di-glycosyl polyene esters of crocetin. The high glycosyl content makes crocins unusual water-soluble carotenoids.
Crocin is a chemical diester composed of the dicarboxylic acid crocetin and disaccharide gentiobiose. Crocins are crocetin glycosyl esters generated via the esterification of crocetin with various glycosides, including geometric isomers. The major active component of saffron is the yellow pigment crocin-2 (three other derivatives with different glycosylations are known) containing a gentiobiose group at each end of the molecule. The five major biologically active components of saffron — the four crocins and crocetin — can be measured with HPLC-UV.
The relationship between crocin and its aglycone crocetin is metabolically important: crocin ingested orally is hydrolysed to crocetin in the gut, which is absorbed across the intestinal barrier, and that crocetin can permeate the blood–brain barrier. Saffron's distinctive golden-yellow color originates from the water-soluble crocin and lipophilic crocetin compounds.
Crocin, a bioactive natural product isolated from Gardenia jasminoides Ellis and Crocus sativus (saffron), is a water-soluble carotenoid that contributes to the red color of saffron. The main sources of these natural compounds are the dried stigmas of Crocus sativus L. (commonly named saffron) and the fruits of Gardenia jasminoides E. C. sativus L. is a perennial herb, belonging to the Iridaceae family, and is widely cultivated in the Mediterranean area and western Asia, with Iran being its main producer.
In China, the contents of gardenia fruits are used as herbal remedies and natural colors. Other plants, such as Buddleja spp., also generate crocins, but because of their low concentration, they are not commercially utilized. More recently, mullein (Verbascum sp.) has been identified as a new source of crocins and picrocrocin.
The biosynthesis of crocin proceeds from the cleavage of carotenoid precursors: crocins and picrocrocin are high-value apocarotenoids rarely found in plants. Both are derived from zeaxanthin cleavage in saffron and Buddleja by a 7,8:7′,8′ reaction catalyzed by carotenoid cleavage dioxygenases (CCDs). Crocin content of the saffron crop is governed by the geographical area where it is grown and the method through which the extraction of crocin is carried out.
Crocin is one of three primary marker compounds used to assess saffron quality. The phytochemical database of saffron contains more than 150 volatile and non-volatile compounds, in which crocetin glycosides or crocin represent one of three major components (safranal, picrocrocin, and crocin) that define saffron quality. More than 150 compounds have been identified in saffron stigma, including colored carotenoids (e.g., crocetin and crocins as glycosidic derivatives), colorless monoterpene aldehydes, volatile agents (e.g., safranal and picrocrocin, which are the bitter components). Crocin gives saffron its golden hue, safranal contributes to its fragrance, and picrocrocin imparts its unique, slightly bitter taste.
As the coloring of saffron is related to the presence of carotenoids, especially crocin, the ISO 3632-1:2011 standard (last reviewed and confirmed in 2017 and currently in force), which establishes specifications for dried saffron obtained from the pistils of C. sativus L. flowers, was applied to obtain information on crocin content. The international benchmark evaluates saffron based on three measurements, with crocin content measured as coloring strength at 440 nm wavelength; Category I saffron (the highest grade) requires a crocin coloring strength reading of over 200.
The dried stigma of the Crocus sativus L. flowers has been used for 4,000–5,000 years as a dye, seasoning, perfume, and medicinal plant. The first authentic phytotherapeutic document of its use is the wall paintings in Thera (Santorini) (1800 BC), on which a woman is seen treating her wounded foot with saffron. In Ancient Cultures (Akkadian, Mesopotamia, Greece, Rome), it was equally a symbol of wealth. Saffron was the dye of some old wall paintings and royal garments.
Roman women used saffron to dye their hair and textiles yellow. ("Saffron," as it happens, comes from the Arabic zafaran, meaning "yellow.") Medicinally, it was powdered and processed to heal everything from rheumatism to measles. According to Pliny, saffron in wine was a popular remedy for a hangover.
In ancient Iran (Persia), only the royal cook was allowed to use saffron while preparing the dishes. The Kurdish culinary culture used Crocus for centuries, mainly in nomadic pastoralism. It also means that in the Middle East the plant has been used for centuries, alike in India and in Spain.
Saffron has traditionally been used for its sedative, emmenagogue, stimulant (appetite), aphrodisiac, diaphoretic, and antidepressant properties, and for a wide variety of conditions, including cramps, asthma, menstrual disorders, liver disease, and pain. From the 17th to 19th centuries, saffron was included in various opioid preparations, including laudanum and "black-drop," for pain relief. In the Indian Ayurvedic health system, saffron is considered an adaptogen.
In traditional medicine, saffron is used as a carminative, antispasmodic, and diaphoretic. An easy way to include saffron in the diet is to add it to rice and vegetables or make a tea by adding several threads to a ginger and honey tea. Zafran (saffron) is a highly valued Unani medication that has been shown to improve immunological function, neuroprotection, mood enhancement, and heart health due to active components such as crocin, crocetin, picrocrocin, and safranal.
The use of saffron as an alternative dye is advantageous in the field of agro-food thanks to the high solubility of crocin in water. Thus, the powerful dyeing power of saffron has been used for a long time to color butter, pasta, cheeses, and oleomargarines. Historically, and particularly in traditional Persian medicine, saffron has been regarded as an abortifacient agent. Farmer women exposed to saffron had increased rates of miscarriage. This could be due to the fact that saffron stimulates uterine contractions.
Crocin, a water-soluble carotenoid, is known as a pharmacologically active compound, particularly for its potent anti-oxidant activity. These phytoconstituents are radical-scavengers, particularly against superoxide anions. Reducing reactive oxygen species (ROS) and malondialdehyde (MDA) and increasing superoxide dismutase (SOD) levels indicate the anti-oxidant effects of crocin. Its antioxidant action is supported by decreased malondialdehyde (MDA) levels and restored glutathione (GSH) content.
Crocin can show anti-inflammatory activities via decreasing tumor necrosis factor-alpha (TNF-α) and interleukin levels. Crocin exerts direct antioxidant, antiapoptotic, and anti-inflammatory activities by multiple signaling pathways. Among the specific pathways documented in preclinical research, crocin has been shown to act on NF-κB and COX-2 signaling.
Recent studies reported that crocin, a carotenoid chemical compound common in crocus and gardenia flowers, has protective effects in neurodegenerative disorders due to its anti-oxidative, anti-inflammatory, and anti-apoptotic properties in the nervous system. Crocin was found to elevate dopamine levels in the brain in the experimental model of Parkinson's disease. Protective effects of crocin on Alzheimer's and Parkinson's disease are caused by its interaction with opioid systems. It is also suggested that antiepileptic effects of crocin and its effects on ketamine withdrawal may be related to an interaction between crocin, GABA, and the opioid system.
A critical pharmacological consideration for crocin is its bioavailability. Pharmacokinetic studies indicate that crocin (CR) has poor bioavailability and needs to convert to crocetin (CC) in order to cross the blood-brain barrier. The orally administered crocin (single or repeated doses, 6 days) is not absorbed via the intestinal tract of rats and is mainly excreted through the colon. The low concentrations of crocetin (by hydrolysis of crocin) were also detected in plasma. Digestion resulted in 40% bioaccessibility for crocin isomers, whereas safranal content followed an opposite trend, increasing about 2-fold its initial concentration after the digestion process.
The antitumor mechanisms of crocin are apoptosis, inhibition of cell proliferation and cell cycle progression, reduction of MRP1 and MRP2 gene expression, inhibition of telomerase activity, microtubule polymerization, and suppression of cyclin D1 and p21Cip1 overexpression. Moreover, this carotenoid can reduce N-cadherin and beta-catenin expression, increase expression of E-cadherin, and down-regulate matrix metalloproteinases 2 and 9, and urokinase-type plasminogen activator expression/activity in tumor cells.
The neuropsychiatric effects of crocin are among the best-studied areas in clinical research. A randomized, double-blind, placebo-controlled, pilot clinical trial was carried out over 4 weeks in two groups of 40 MDD patients (aged 24–50) at Ibn-e-Sina psychiatric hospital in Iran. The crocin group (n=20) was given one SSRI (fluoxetine 20 mg/day, sertraline 50 mg/day, or citalopram 20 mg/day) plus crocin tablets (30 mg/day; 15 mg BID), while the placebo group received an SSRI plus placebo for 4 weeks. An adjunctive study using crocin (an active ingredient of saffron; 15 mg twice daily) demonstrated additive effects alongside selective serotonin reuptake inhibitors (SSRIs).
A randomized trial in patients on methadone maintenance treatment (MMT) provides additional human evidence. Patients under MMT were randomly allocated to receive either 30 mg/day crocin (2 plus crocin tablet, 15 mg BID) (n=25) or placebo (n=25), one hour after taking food, for 8 weeks. After 8-week intervention, crocin significantly decreased Beck Depression Inventory (b −6.66; 95% CI, −9.88, −3.45; P < 0.0001), Beck Anxiety Inventory (b −4.35; 95% CI, −5.94, −2.75; P < 0.0001), general health questionnaire, and Pittsburgh Sleep Quality Index in patients under MMT, compared with placebo. Crocin also significantly improved International Index of Erectile Functions (b 4.98; 95% CI, 2.08, 7.88; P = 0.001) compared to placebo.
Broader saffron extract research also informs the crocin evidence base. In depression, RCTs using 30 mg/day of saffron for six weeks showed comparable improvements in Hamilton Depression Rating Scale (HAM-D) scores to fluoxetine (20 mg/day), with significant reductions from baseline and no difference in adverse events. Meta-analyses confirm the superiority of saffron over placebo and its equivalence to conventional drugs, with no serious adverse events reported. Saffron represents a safe, well-tolerated, and culturally integrated intervention with growing evidence for use in psychiatric and neurologic disorders. Evidence strength: Moderate. Multiple RCTs exist, though most are small, predominantly Iranian, and of short duration. Larger multicenter trials are required.
The first major study in this area was conducted from 2007 to 2009 in a multicenter, randomized, double-blind format. Two groups of 27 patients with mild-to-moderate AD were given either saffron (15 mg/d during the first month and then 30 mg/d to the end) or donepezil (5 mg/d during the first month and then 10 mg/d to the end) for 22 weeks. The findings showed that the effects of the total ethanol extract of saffron on global cognitive and clinical signs, monitored by the ADAS-cog and CDR-SB, were comparable to the effects of donepezil, with fewer side effects (vomiting).
In cognitive disorders, saffron (30 mg/day) showed non-inferiority to donepezil (10 mg/day) and memantine (20 mg/day) in patients with mild-to-moderate and moderate-to-severe AD. Trials lasting 16 to 52 weeks demonstrated significant improvements on validated cognitive scales such as the ADAS-Cog and CDR-Sum of Boxes.
A systematic review and meta-analysis of four RCTs confirmed these findings: the analysis revealed that saffron significantly improves cognitive function measured by the ADAS-cog and CDR-SB, compared to placebo groups. There was no significant difference between saffron and conventional medicine as measured by cognitive scales. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported.
A smaller single-blind trial in mild cognitive impairment (MCI) reported that 17 patients on Crocus sativus and 18 on a waiting list were examined with a short neuropsychological battery and MRI at baseline and after 12 months. The results showed that patients on Crocus had improved Mini-Mental State Examination scores (p = 0.015), while the control group deteriorated. Evidence strength: Moderate for mild-to-moderate Alzheimer's disease, with replicated non-inferiority findings. Limited by small sample sizes and the fact that most trials used total saffron extract rather than isolated crocin. The meta-analysis noted insufficient evidence to make clinical recommendations due to limited high-quality studies.
Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer's disease and mild cognitive impairment. However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use.
A number of RCTs have examined crocin's effects on metabolic and cardiovascular risk markers. One study demonstrated that crocin at a dose of 30 mg/d significantly reduced serum pro-oxidant–anti-oxidant balance (PAB) by 11.7% in the intervention group (p = 0.006), with no statistically significant differences in fasting blood glucose (FBG) and blood lipid profile (cholesterol, triglycerides, LDL, and HDL) between the two groups before and after the intervention. This study demonstrates that crocin, a derivative of saffron, at a dose of 30 mg/d can significantly reduce serum PAB in individuals with metabolic syndrome.
A 2021 pilot RCT assessed HDL cholesterol uptake capacity (CUC): forty-four subjects with metabolic syndrome were randomly allocated to one of two groups: one group received placebo and the other group received crocin at a dose of 30 mg (two tablets of 15 mg per day) for 8 weeks.
A 2020 systematic review and meta-analysis of eight eligible studies confirmed selective effects: results of the pooled random-effect size analysis showed a significant decreasing effect of crocin supplementation on fasting blood glucose (WMD: −6.52 mg/L, 95% CI, −11.96, −1.08; p = 0.019) and total cholesterol (WMD: −4.64 mg/L, 95% CI, −8.19, −1.09; p = 0.010). Crocin supplements did not have any significant effect on serum TG, LDL-C, or HDL-C levels. Results showed that crocin supplementation could beneficially affect TG levels only when trial duration was less than 12 weeks and LDL-C levels in trials that used high-dose intervention and that were conducted on subjects with metabolic disorders.
More recent human data on inflammatory cytokines in metabolic syndrome found that twenty-eight patients with metabolic syndrome were randomly selected in a double-blind randomized clinical trial. Participants were divided into two groups: one received 15 mg of crocin (two tablets per day) and the other received placebo for eight weeks. Inflammatory and growth factors were measured using a sandwich chemiluminescence assay. Results indicated that inflammatory factors including IL-2, IL-10, VEGF, and INF-γ were significantly reduced (P < 0.05) in patients with metabolic syndrome after crocin treatment. No significant difference was detected among other biochemical factors (lipid profile and FBG) between the two groups. Evidence strength: Preliminary-to-moderate. Consistent signal for antioxidant and some glycemic effects in small trials; lipid outcomes are inconsistent across trials.
Crocins and related active constituents derived from saffron have demonstrated protective effects against cerebral ischemia and ischemic stroke, with various bioactivities including neuroprotection, anti-neuroinflammation, antioxidant, and cardiovascular protection. Crocin has been shown to act on multiple mechanisms and signaling pathways involved in ischemic stroke, including mitochondrial apoptosis, NF-κB pathway, S100 calcium-binding protein B, IL-6, and vascular endothelial growth factor-A.
In the context of Parkinson's disease, preclinical evidence is available: crocin was found to elevate dopamine levels in the brain in an experimental model of Parkinson's disease. A recently published randomized controlled clinical trial investigated the effect of 60 mg/day crocin on movement disorders and oxidative DNA damage. However, only movement disorders were significantly improved after 8 weeks intervention.
Neuroprotective effects of crocin have been shown by experimental studies, but not yet confirmed in clinical trials, and more safety studies should be performed to indicate possible toxic effects of crocin in long-term use. Evidence strength: Largely preclinical (animal and in vitro) for Parkinson's disease and cerebral ischemia. Human evidence is very limited and preliminary.
Saffron and crocin showed obvious antiproliferative effects on human cancer cell lines, including colorectal cancer, breast cancer, lung cancer, prostate cancer, cervical cancer, leukemia, glioblastoma, and rhabdomyosarcoma. According to various literature, crocin inhibits tumor growth and its spread in several types of cancer including colorectal, pancreatic, breast, and prostate, as well as chronic myelogenous leukemia.
Mechanistically, in breast cancer cells: the evidence indicated that crocin inhibits cell proliferation by targeting tubulin. These results suggest that crocin has potential to be developed as an anticancer agent. In hepatocellular carcinoma: the expression of key genes involved in carcinogenesis (TNF-α, p53, VEGF, and NF-κB) was highly activated in hepatocellular carcinoma and was significantly attenuated after treatment with crocin or sorafenib or the combination of both. The combination group showed more favorable performance in improving histopathological and inflammatory response than monotherapy. The administration of crocin or sorafenib alone or their combination produced cytotoxicity and anti-cancer effects on HepG2 cells, and the combination of crocin and sorafenib had synergistic antitumor effects.
One clinical observation noted that data from a clinical trial indicated that using crocin during chemotherapy in breast cancer patients ameliorated their anxiety and depression. However, before saffron and crocin can be used in clinical settings, well-designed controlled clinical trials should be conducted, including compound pharmacokinetic analysis and further exploration of their mechanisms of action in cancer management. Evidence strength: Predominantly in vitro and animal studies. No large-scale human RCTs have confirmed clinical anticancer outcomes. This area remains investigational.
A 2025 systematic review specifically evaluated crocin's effects on Alzheimer's and Parkinson's disease: the review aimed to provide a comprehensive overview of the neuroprotective effects of crocin in Alzheimer's and Parkinson's diseases based on anti-oxidative, anti-inflammatory, and cytoprotective properties. Due to few studies of these beneficial effects in humans, the limitation of confirmation of these effects in humans through clinical trials, as well as accomplished in vitro tests with non-physiological metabolites and/or concentrations, the review focused on anti-inflammatory, antioxidant, and cytoprotective effects of crocin in in vivo models.
Crocin is available in several preparations, both as isolated constituent tablets and as part of standardized saffron extract formulations.
Crocin is generally safe and well-tolerated. Crocin has been demonstrated to be a promising option for the treatment of neurodegenerative diseases, with few adverse effects. No serious adverse events were reported in included clinical studies for mild cognitive impairment and dementia trials.
Animal toxicology data generally indicates a low acute toxicity profile for crocin: crocin-I did not damage any major organs in rats and mice by acute and sub-acute toxicity tests (up to 3 g/kg, PO and IP, 2 days, as well as 180 mg/kg, IP, 21 days). With high doses (3 g/kg, IP or orally), after 24 and 48 hours no mortality was seen in mice. According to Loomis and Hayes classification, chemical substances with LD50 values within the range of 1–5 g/kg are considered as practically low-toxic.
However, some caution is warranted regarding hepatic effects: Wang et al. found that crocins could cause slight reversible liver dysfunction in rats after oral administration. The damage appears to be related to the gradual accumulation of crocin, but the probability of this occurring in humans is very low.
There is insufficient data on the toxicological evaluation of crocin in humans for giving safety assurance in developing this constituent of saffron as a medicine.
This is the most well-documented safety concern for saffron and its crocin constituent. Avoid use in pregnancy. Amounts higher than those used in food (e.g., 5 g or more) have uterine stimulant and abortifacient effects. Information regarding safety and efficacy in lactation is lacking.
Historically, and particularly in traditional Persian medicine, saffron has been regarded as an abortifacient agent. Farmer women exposed to saffron had increased rates of miscarriage. This could be due to the fact that saffron stimulates uterine contractions.
Experimental animal data on crocin specifically: crocin was able to significantly reduce progesterone in the late stages of pregnancy, and high doses of saffron and crocin can decrease the number of fetuses. Administration of crocin and safranal in pregnant mice caused documented fetal malformations: minor skeletal malformations, malformations of the mandible and calvaria, and growth retardation. Although this is an animal model, the precautionary principle mandates a formal contraindication in pregnant women. No study has evaluated the passage of active compounds into breast milk. On a precautionary basis, supplementation is inadvisable throughout the entire duration of breastfeeding.
Conflicting results regarding saffron's effect on human platelets in healthy volunteers were reported, while an aqueous extract of saffron inhibited human platelet aggregation in vitro. Interactions with anti-aggregating drugs are theoretically possible; saffron is contraindicated in bleeding disorders. Crocetin binds strongly to serum albumin; however, displacement of plasma-bound drugs has not been evaluated. Rivaroxaban: saffron may enhance the anticoagulant effect of rivaroxaban.
Pharmacokinetic studies indicate that crocin has poor bioavailability and needs to convert to crocetin in order to cross the blood-brain barrier. Its effectiveness is limited due to low bioavailability, poor absorption, and low physicochemical stability. Researchers have explored nanotechnology-based formulations to address this limitation, though clinical data on such preparations remain preliminary.
Health conditions that Crocin may help support.
Crocin is the primary active glycoside of saffron (Crocus sativus) and is the precursor metabolized to crocetin in the body. Multiple clinical trials demonstrate that supplementation with saffron extract (containing crocin as the key active) at 20–50 mg/day significantly improved retinal function, visual acuity, and contrast sensitivity in AMD patients. It acts via antioxidant, anti-inflammatory, neuroprotective, and anti-angiogenic mechanisms in ocular tissues.
Body systems that Crocin may help support.
Go back